Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedJan 14, 2026
DataAggregated Company Financials
Companies9
  • 7D2.1%
  • 3M15.3%
  • 1Y30.4%
  • YTD4.2%

Over the last 7 days, the Pharma industry has risen 2.1%, driven by gains from Roche Holding of 3.3%. This takes the industry's 12 month performance to a gain of 30%. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 14 Jan 2026CHF 579.1bCHF 121.4bCHF 21.6b35.6x26.8x4.8x
Fri, 12 Dec 2025CHF 545.8bCHF 120.9bCHF 21.5b33.5x25.4x4.5x
Sun, 09 Nov 2025CHF 488.1bCHF 121.7bCHF 21.6b32.3x22.6x4x
Tue, 07 Oct 2025CHF 512.8bCHF 120.1bCHF 20.9b33.9x24.5x4.3x
Thu, 04 Sep 2025CHF 490.8bCHF 120.7bCHF 21.0b30.9x23.3x4.1x
Sat, 02 Aug 2025CHF 459.5bCHF 120.6bCHF 20.9b23.2x22x3.8x
Mon, 30 Jun 2025CHF 450.4bCHF 117.5bCHF 19.0b25.1x23.8x3.8x
Wed, 28 May 2025CHF 439.7bCHF 119.3bCHF 19.3b25.1x22.8x3.7x
Fri, 25 Apr 2025CHF 424.6bCHF 118.0bCHF 18.5b25.2x22.9x3.6x
Sun, 23 Mar 2025CHF 487.4bCHF 121.8bCHF 19.2b29.7x25.4x4x
Tue, 18 Feb 2025CHF 475.6bCHF 122.5bCHF 19.1b22.9x24.8x3.9x
Thu, 16 Jan 2025CHF 443.2bCHF 119.9bCHF 21.5b18.4x20.6x3.7x
Sat, 14 Dec 2024CHF 420.5bCHF 118.6bCHF 21.2b17.9x19.8x3.5x
Mon, 11 Nov 2024CHF 439.1bCHF 117.4bCHF 21.0b18.9x20.9x3.7x
Wed, 09 Oct 2024CHF 449.4bCHF 115.4bCHF 19.4b21.3x23.2x3.9x
Fri, 06 Sep 2024CHF 461.4bCHF 114.5bCHF 19.3b22.1x24x4x
Sun, 04 Aug 2024CHF 458.6bCHF 115.3bCHF 19.5b22.6x23.5x4x
Tue, 02 Jul 2024CHF 435.1bCHF 116.7bCHF 19.8b33.7x22x3.7x
Thu, 30 May 2024CHF 405.6bCHF 117.4bCHF 19.9b42.1x20.4x3.5x
Sat, 27 Apr 2024CHF 394.0bCHF 113.6bCHF 20.0b37.3x19.7x3.5x
Mon, 25 Mar 2024CHF 386.2bCHF 111.7bCHF 19.3b37.5x20x3.5x
Wed, 21 Feb 2024CHF 388.5bCHF 110.4bCHF 19.7b24.6x19.7x3.5x
Fri, 19 Jan 2024CHF 414.1bCHF 120.4bCHF 18.8b27x22x3.4x
Sun, 17 Dec 2023CHF 394.8bCHF 120.6bCHF 18.8b24.6x21x3.3x
Tue, 14 Nov 2023CHF 388.5bCHF 122.6bCHF 19.1b23.7x20.4x3.2x
Thu, 12 Oct 2023CHF 412.9bCHF 121.6bCHF 18.6b26.9x22.2x3.4x
Sat, 09 Sep 2023CHF 401.2bCHF 112.4bCHF 18.0b47.1x22.3x3.6x
Mon, 07 Aug 2023CHF 409.2bCHF 111.4bCHF 17.9b48.3x22.9x3.7x
Wed, 05 Jul 2023CHF 419.3bCHF 115.2bCHF 18.9b36.7x22.2x3.6x
Fri, 02 Jun 2023CHF 429.9bCHF 115.7bCHF 19.0b37.2x22.7x3.7x
Sun, 30 Apr 2023CHF 429.2bCHF 115.0bCHF 18.9b41x22.8x3.7x
Tue, 28 Mar 2023CHF 405.9bCHF 115.8bCHF 19.0b41.6x21.4x3.5x
Thu, 23 Feb 2023CHF 410.7bCHF 116.5bCHF 19.1b28.2x21.5x3.5x
Sat, 21 Jan 2023CHF 435.1bCHF 117.0bCHF 34.6b23.4x12.6x3.7x
Price to Earnings Ratio

12.6x


Total Market Cap: CHF 435.1bTotal Earnings: CHF 34.6bTotal Revenue: CHF 117.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.1x202420252026
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 26.8x which is higher than its 3-year average PE of 22.1x.
  • The 3-year average PS ratio of 3.7x is lower than the industry's current PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 15% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market0.32%
Healthcare2.09%
Pharma2.08%
Pharma2.08%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROG Roche HoldingCHF 340.903.3%
+CHF 9.4b		29.4%PE30.7x
NOVN NovartisCHF 113.641.9%
+CHF 4.1b		26.1%PE18.9x
SDZ Sandoz GroupCHF 59.240.6%
+CHF 155.1m		53.9%PE140.4x
NWRN Newron PharmaceuticalsCHF 27.8511.4%
+CHF 57.0m		212.6%PE23.6x
CURN Curatis HoldingCHF 16.8533.2%
+CHF 21.6m		16.6%n/a

Latest News

GALD
CHF 158.90
Galderma Group
7D
-4.0%
1Y
46.0%
DESN
CHF 355.00
Dottikon ES Holding
7D
-2.7%
1Y
69.5%

Does Dottikon ES Holding (VTX:DESN) Deserve A Spot On Your Watchlist?

Jan 14
Does Dottikon ES Holding (VTX:DESN) Deserve A Spot On Your Watchlist?
ADXN
CHF 0.055
Addex Therapeutics
7D
4.6%
1Y
-10.5%
NOVN
CHF 113.64
Novartis
7D
1.9%
1Y
26.1%

NOVN: Future Returns Will Reflect US Buildout And Late-Stage Pipeline Delivery

Analysts have raised their price target for Novartis to $109.99 from $106.64, citing updated assumptions for slightly stronger revenue growth, higher profit margins, and a modestly lower future P/E multiple. What's in the News Novartis plans a new 35,000 square foot radioligand therapy manufacturing facility in Winter Park, Florida, as part of its previously announced US$23b US investment.
COPN
CHF 103.80
Cosmo Pharmaceuticals
7D
-4.8%
1Y
63.7%

COPN: EU Acne Authorization And Rollout Will Likely Leave Shares Overextended

Analysts have trimmed their price target for Cosmo Pharmaceuticals by roughly €0.46, reflecting slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple in their updated models. What's in the News The European Commission granted Marketing Authorization for Winlevi (clascoterone 10 mg/g cream), following a prior positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use issued on August 25, 2025 (Key Developments).
ROG
CHF 340.90
Roche Holding
7D
3.3%
1Y
29.4%

ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution

Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.
NWRN
CHF 27.85
Newron Pharmaceuticals
7D
11.4%
1Y
212.6%
SDZ
CHF 59.24
Sandoz Group
7D
0.6%
1Y
53.9%

SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks

Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.
BIOV
CHF 22.70
BioVersys
7D
-0.9%
1Y
n/a
CURN
CHF 16.85
Curatis Holding
7D
33.2%
1Y
16.6%